Abstract
Here, we develop a genetics-anchored framework to decipher mechanisms of infectious disease (ID) risk and infer causal effect on potential complications. We perform transcriptome-wide association studies (TWAS) of 35 ID traits in 27,615 individuals in a broad collection of human tissues, identifying 70 gene-level associations with 26 ID traits, with replication in two large-scale biobanks. A phenome-scale scan and Mendelian Randomization of the 70 gene-level associations across 197 traits proposes a molecular basis for known complications of the ID traits. This rich resource of host genetic associations with pathogen cultures and 16S-rRNA-based microbiome variation provides a platform to investigate host-pathogen interactions. To identify relevant cellular processes, we develop a TWAS repository of 79 pathogen-exposure induced cellular phenotypes. Our study will facilitate mechanistic insights into the role of host genetic variation on ID risk and pathophysiology, with important implications for our molecular understanding of severe phenotypic outcomes.
Competing Interest Statement
E.R.G. receives an honorarium from the journal Circulation Research of the American Heart Association, as a member of the Editorial Board. He performed consulting on pharmacogenetic analysis with the City of Hope / Beckman Research Institute.
Funding Statement
A.T.H. is supported by the National Institutes of Health (F30HL143826) and Vanderbilt University Medical Scientist Training Program (T32GM007347). E.R.G. is supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R35HG010718. E.R.G and S.S.Z. are funded by the National Heart, Lung, & Blood Institute of the National Institutes of Health under Award Number R01HL133559. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. E.R.G. has also significantly benefitted from a Fellowship at Clare Hall, University of Cambridge (UK) and is grateful to the President and Fellows of the college for a stimulating intellectual home. Genomic data are also supported by individual investigator-led projects including U01-HG004798, R01-NS032830, RC2-GM092618, P50-GM115305, U01-HG006378, U19-HL065962, and R01-HD074711. Additional funding sources for BioVU are listed at https://victr.vanderbilt.edu/pub/biovu/. L.B. is supported by R01-LM010685. S.J.S. is supported R01-EB1019804, R01-AI145057, R01-EB014641, R01-HD085853, and DP1-HD086071. D.C.K. is supported by R01-AI118903, R21-AI144586, and R21-AI146520. D.C.K. and L.W. are supported by R21-AI133305.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Vanderbilt University Medical Center IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All results and code are available at the links below.
